Stifel Financial
EFTR

Stifel Financial’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Stifel Financial’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-906
Closed -$10.6K – 3449
2023
Q4 		$10.6K Hold
906
– – ﹤0.01% 3295
2023
Q3 		$13.6K Buy
+906
New +$15.7K ﹤0.01% 3258

Other funds holding EFTR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Stifel Financial's EFTR Position: Q1 2024 in Review

Stifel Financial sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q1 2024, closing a stake of 906 shares — an estimated $10.6K sold.

Stifel Financial first reported a position in EFTR in Q3 2023 and held it in 2 quarters. The position peaked at $13.6K in Q3 2023. 17 funds tracked by Wall St. Rank hold EFTR as of Q1 2024.

  • Stifel Financial reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Stifel Financial sold 906 eFFECTOR Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $10.6K.
  • Stifel Financial first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Stifel Financial's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $13.6K in Q3 2023.
  • 17 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Stifel Financial's 13F filing for Q1 2024, filed 14 May 2024.